Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral versus intravenous nicorandil for coronary microcirculation protection in elective PCI
ChiCTR1800020073Phase 4Completed
- Sponsor
- Peking University Third Hospital
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nicorandil in coronary arteriosclerosis (3 arms), sponsored by Peking University Third Hospital. Primary endpoint: Index of microcirculatory resistance. Started Nov 2016; status: completed.
02
Drugs
nicorandil
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1800020073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020073.